Skip to main content
. 2023 Jan 4;12:1104810. doi: 10.3389/fonc.2022.1104810

Table 4.

Univariable and multivariable Cox regression analyses for RFS of pCCA patients.

Variables Comparison Univariable analyses Multivariable analyses*
P value HR (95% CI) P value HR (95% CI)
Age > 60 vs. ≤ 60 years 0.115 1.011 (0.997-1.021)
Gender Male vs. Female 0.353 0.889 (0.692-1.139)
ASA score > 2 vs. ≤ 2 0.996 1.001 (0.779-1.281)
Comorbidity Yes vs. No 0.295 1.158 (0.878-1.541)
Preoperative jaundice Yes vs. No 0.199 1.982 (0.911-1.582)
ALB < 35 vs. ≥ 35 g/L 0.138 0.823 (0.641-1.072)
ALT > 40 vs. ≤ 40 U/L 0.077 1.326 (0.971-1.836)
AST > 40 vs. ≤ 40 U/L 0.350 1.162 (0.851-1.592)
NLR* < 1.68 vs. ≥ 1.68 <0.001 1.938 (1.511-2.479) <0.001 1.598 (1.224-2.088)
PLR* < 113.1 vs. ≥ 113.1 <0.001 2.772 (2.121-3.623) <0.001 2.138 (1.613-2.833)
CA 19-9* > 150 vs. ≤ 150 U/L 0.006 1.516 (1.132-2.047) 0.227 1.210 (0.888-1.649)
INR > 1.25 vs. ≤ 1.25 0.503 1.192 (0.711-1.992)
Cirrhosis Yes vs. No 0.836 1.050 (0.671-1.639)
Chronic hepatitis Yes vs. No 0.375 0.822 (0.521-1.280)
Hepatolithiasis Yes vs. No 0.269 1.286 (0.821-2.005)
Maximum tumor size* < 3 cm vs. ≥ 3 cm 0.002 1.491 (1.162-1.912) 0.011 1.398 (1.080-1.812)
Tumor differentiation* poor vs. well/moderate <0.001 1.931 (1.403-2.659) 0.099 1.411 (0.937-2.124)
Macrovascular invasion* Yes vs. No 0.001 1.592 (1.221-2.093) 0.031 1.367 (1.030-1.815)
Microvascular invasion* Yes vs. No <0.001 2.179 (1.531-3.108) 0.239 1.313 (0.835-2.065)
Peripheral nerve invasion Yes vs. No 0.637 1.071 (0.822-1.389)
lymph node metastasis* Yes vs. No <0.001 2.047 (1.593-2.629) <0.001 1.638 (1.246-2.154)
Extent of hepatectomy Major vs. Minor 0.784 1.039 (0.791-1.364)

*Those variables found significant at P <.100 in univariable analyses were entered into multivariable Cox regression analyses.

ALB, albumin level; ALT, alanine aminotransferase; ASA, American Society of Anesthesiologists; AST, aspartate transaminase; CA19-9, carbohydrate antigen 19-9; CI, confidence interval; HR, hazard ratio; INR, international normalized ratio; NLR, neutrophil-to-lymphocyte ratio; pCCA, perihilar cholangiocarcinoma; PLR, platelet-to-lymphocyte ratio; PLT, platelet level; RFS, recurrence-free survival; TB, total bilirubin.